 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 July 1999 | Volume 131 Issue 2 | Pages 81-87
Background: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection. The performance of such therapy outside of the clinical trial setting is unclear.
Objective: To determine factors associated with failure to suppress HIV-1 RNA levels and adverse drug reactions in a cohort of patients in whom protease inhibitor-containing therapy was begun in a large urban clinic.
Design: Retrospective cohort study.
Setting: Johns Hopkins HIV Clinic in Baltimore, Maryland.
Patients: 273 protease inhibitor-naive patients began taking a protease inhibitor regimen containing at least one other antiretroviral drug to which the patients had not previously been exposed.
Measurements: Demographic variables, plasma HIV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions.
Results: Levels of HIV-1 RNA were undetectable in 42% of the cohort at 1 to 90 days, in 44% at 3 to 7 months, and in 37% at 7 to 14 months. Factors associated with failure to suppress viral load at two or more time points included higher rates of missed clinic appointments, nonwhite ethnicity, age 40 years or younger, injection drug use, lower baseline CD4+ lymphocyte count, and higher baseline viral load. In a multivariate model, only higher rates of missed clinic appointments were independently associated with viral suppression at 1 year. Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or nelfinavir, and women experienced significantly more adverse effects than men.
Conclusions: Unselected patients in whom HAART is started in a clinic setting achieve viral suppression substantially less frequently than do patients in controlled clinical trials. Missed clinic visits were the most important risk factor for failure to suppress HIV-1 RNA levels. Studies are needed to identify interventions that maximize the performance of HAART in inner-city clinics.
Author and Article Information
From Johns Hopkins University School of Medicine, Baltimore, Maryland.
Grant Support: By the Agency for Health Care Policy and Research (R01-H507809) and the National Institute on Drug Abuse (R01-DA11602).
Requests for Reprints: Richard D. Moore, MD, MHSc, 1830 East Monument Street, Room 8059, Baltimore, MD 21205.
Current Author Addresses: Drs. Lucas, Chaisson, and Moore: 1830 East Monument Street, Room 455, Baltimore, MD 21205. ARTICLE
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions
This article has been cited by other articles:
|
|
 |
|
  J. D. Hartzell, I. E. Janke, and A. C. Weintrob Impact of depression on HIV outcomes in the HAART era J. Antimicrob. Chemother., August 1, 2008; 62(2): 246 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, A. M. Bayoumi, M. Holodniy, and D. K. Owens Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med, June 17, 2008; 148(12): 889 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
|
|
H. J. M. ter Hofstede, P. P. Koopmans, and D. M. Burger Stavudine plasma concentrations and lipoatrophy J. Antimicrob. Chemother., April 1, 2008; 61(4): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Park, J. Y. Kim, S.-H. Kim, H. B. Kim, N. J. Kim, M.-D. Oh, and K. W. Choe Self-reported reasons among HIV-infected patients for missing clinic appointments Int J STD AIDS, February 1, 2008; 19(2): 125 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Nachega, M. Hislop, D. W. Dowdy, R. E. Chaisson, L. Regensberg, and G. Maartens Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes Ann Intern Med, April 17, 2007; 146(8): 564 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R C. Rathbun, K. C Farmer, S. M Lockhart, and J. R Stephens Validity of a Stage of Change Instrument in Assessing Medication Adherence in Indigent Patients with HIV Infection Ann. Pharmacother., February 1, 2007; 41(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Williams, D. Storm, G. Montepiedra, S. Nichols, B. Kammerer, P. A. Sirois, J. Farley, K. Malee, and for the PACTG 219C Team Predictors of Adherence to Antiretroviral Medications in Children and Adolescents With HIV Infection Pediatrics, December 1, 2006; 118(6): e1745 - e1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie, Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P. Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, et al. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire N. Engl. J. Med., September 14, 2006; 355(11): 1141 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. A. Stringer, I. Zulu, J. Levy, E. M. Stringer, A. Mwango, B. H. Chi, V. Mtonga, S. Reid, R. A. Cantrell, M. Bulterys, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA, August 16, 2006; 296(7): 782 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Lucas, M. Griswold, K. A. Gebo, J. Keruly, R. E. Chaisson, and R. D. Moore Illicit Drug Use and HIV-1 Disease Progression: A Longitudinal Study in the Era of Highly Active Antiretroviral Therapy Am. J. Epidemiol., March 1, 2006; 163(5): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grabar, L. Weiss, and D. Costagliola HIV infection in older patients in the HAART era J. Antimicrob. Chemother., January 1, 2006; 57(1): 4 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hardy Adherence to Antiretroviral Therapy: The Emerging Role of HIV Pharmacotherapy Specialists Journal of Pharmacy Practice, August 1, 2005; 18(4): 247 - 257. [Abstract] [PDF]
|
|
|
|
 |
|
 M. F. Parry, P. Wright, J. Stewart, G. X. McLeod, J. Tucker, and A. R. Weinberg Impact of an Adherence Program on the Health and Outlook of HIV-Infected Patients Failing Antiretroviral Therapy. J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 59 - 65. [Abstract] [PDF]
|
|
|
|
|
|
K. Shannon, T. Kerr, C. Lai, T. Ishida, E. Wood, J. S. G. Montaner, R. S. Hogg, and M. W. Tyndall Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2005; 4(3): 66 - 72. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Martinez-Picado, T. Wrin, S. D. W. Frost, B. Clotet, L. Ruiz, A. J. L. Brown, C. J. Petropoulos, and N. T. Parkin Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1 J. Virol., May 15, 2005; 79(10): 5907 - 5913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Chu, S. J. Gange, K. Anastos, H. Minkoff, H. Cejtin, M. Bacon, A. Levine, and R. M. Greenblatt Hormonal Contraceptive Use and the Effectiveness of Highly Active Antiretroviral Therapy Am. J. Epidemiol., May 1, 2005; 161(9): 881 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Resino, J. M. Bellon, J. T. Ramos, M. Gonzalez-Rivera, M. I. de Jose, M. I. Gonzalez, D. Gurbindo, M. J. Mellado, E. Cabrero, and M. A. Munoz-Fernandez Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study J. Antimicrob. Chemother., November 1, 2004; 54(5): 921 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L Anderson Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy Ann. Pharmacother., November 1, 2004; 38(11): 1924 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Smit, B. J. Brew, W. Tourtellotte, S. Morgello, B. B. Gelman, and N. K. Saksena Independent Evolution of Human Immunodeficiency Virus (HIV) Drug Resistance Mutations in Diverse Areas of the Brain in HIV-Infected Patients, with and without Dementia, on Antiretroviral Treatment J. Virol., September 15, 2004; 78(18): 10133 - 10148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Greenberg and N. Cammack Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother., August 1, 2004; 54(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Hazuda, S. D. Young, J. P. Guare, N. J. Anthony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt, S. L. Motzel, H. J. Klein, et al. Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques Science, July 23, 2004; 305(5683): 528 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Crepaz, T. A. Hart, and G. Marks Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-analytic Review JAMA, July 14, 2004; 292(2): 224 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Jabs AIDS and Ophthalmology in 2004 Arch Ophthalmol, July 1, 2004; 122(7): 1040 - 1042. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Turner, M. Weiner, C. Yang, and T. TenHave Predicting Adherence to Colonoscopy or Flexible Sigmoidoscopy on the Basis of Physician Appointment-Keeping Behavior Ann Intern Med, April 6, 2004; 140(7): 528 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, Y. Zhou, C. Alcock, T. Kiefer, D. Monie, J. Siliciano, Q. Li, P. Pham, J. Cofrancesco, D. Persaud, et al. Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 J. Virol., February 15, 2004; 78(4): 1718 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Montessori, N. Press, M. Harris, L. Akagi, and J. S.G. Montaner Adverse effects of antiretroviral therapy for HIV infection Can. Med. Assoc. J., January 20, 2004; 170(2): 229 - 238. [Abstract] [Full Text]
|
|
|
|
|
|
R. K. Zeldin and R. A. Petruschke Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J. Antimicrob. Chemother., January 1, 2004; 53(1): 4 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Masquelier, C. Droz, M. Dary, C. Perronne, V. Ferre, B. Spire, D. Descamps, F. Raffi, F. Brun-Vezinet, G. Chene, et al. R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3623 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Escobar, M. Campo, J. Martin, C. Fernandez-Shaw, F. Pulido, and R. Rubio Factors Affecting Patient Adherence to Highly Active Antiretroviral Therapy Ann. Pharmacother., June 1, 2003; 37(6): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Kempen, D. A. Jabs, L. A. Wilson, J. P. Dunn, S. K. West, and J. A. Tonascia Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome Arch Ophthalmol, April 1, 2003; 121(4): 466 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H K Thaker and M H Snow HIV viral suppression in the era of antiretroviral therapy Postgrad. Med. J., January 1, 2003; 79(927): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Kuehne, U. Bethe, K. Freedberg, and S. J. Goldie Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness Arch Intern Med, December 9, 2002; 162(22): 2545 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oxenius, D. A. Price, H. F. Gunthard, S. J. Dawson, C. Fagard, L. Perrin, M. Fischer, R. Weber, M. Plana, F. Garcia, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection PNAS, October 15, 2002; 99(21): 13747 - 13752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dybul, A. S. Fauci, J. G. Bartlett, J. E. Kaplan, and A. K. Pau Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV Ann Intern Med, September 3, 2002; 137(5_Part_2): 381 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hammer, F. Vaida, K. K. Bennett, M. K. Holohan, L. Sheiner, J. J. Eron, L. J. Wheat, R. T. Mitsuyasu, R. M. Gulick, F. T. Valentine, et al. Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial JAMA, July 10, 2002; 288(2): 169 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Vilchez, J. L. Jorgensen, and M. H. Kroll Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy Blood, May 13, 2002; 99(11): 4250 - 4251. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Levine Evaluation and Management of HIV-Infected Women Ann Intern Med, February 5, 2002; 136(3): 228 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Demeter, M. D. Hughes, R. W. Coombs, J. B. Jackson, J. M. Grimes, R. J. Bosch, S. A. Fiscus, S. A. Spector, K. E. Squires, M. A. Fischl, et al. Predictors of Virologic and Clinical Outcomes in HIV-1-Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320 Ann Intern Med, December 4, 2001; 135(11): 954 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Phillips, S. Staszewski, R. Weber, O. Kirk, P. Francioli, V. Miller, P. Vernazza, J. D. Lundgren, B. Ledergerber, and for the Swiss HIV Cohort Study, the Frankfurt HIV HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load JAMA, November 28, 2001; 286(20): 2560 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Spiegel, H. Kraemer, R. W. Carlson, C. J. McDonald, F. G. Miller, T. J. Kaptchuk, T. E. Einarson, M. Hemels, P. Stolk, R. J. Lilford, et al. Is the Placebo Powerless? N. Engl. J. Med., October 25, 2001; 345(17): 1276 - 1279. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Katz, W. E. Cunningham, J. A. Fleishman, R. M. Andersen, T. Kellogg, S. A. Bozzette, and M. F. Shapiro Effect of Case Management on Unmet Needs and Utilization of Medical Care and Medications among HIV-Infected Persons Ann Intern Med, October 16, 2001; 135(8_Part_1): 557 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, S. J. Goldie, M. C. Weinstein, E. Losina, H. Zhang, and K. A. Freedberg Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults Am J Public Health, September 1, 2001; 91(9): 1456 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Freedberg, E. Losina, M. C. Weinstein, A. D. Paltiel, C. J. Cohen, G. R. Seage, D. E. Craven, H. Zhang, A. D. Kimmel, and S. J. Goldie The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease N. Engl. J. Med., March 15, 2001; 344(11): 824 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Deeks, T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, et al. Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia N. Engl. J. Med., February 15, 2001; 344(7): 472 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Levine, D. T. Scadden, J. A. Zaia, and A. Krishnan Hematologic Aspects of HIV/AIDS Hematology, January 1, 2001; 2001(1): 463 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kilby, G. Sfakianos, N. Gizzi, P. Siemon-Hryczyk, E. Ehrensing, C. Oo, N. Buss, and M. S. Saag Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2672 - 2678. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Gulick Assessing the Benefits of Antiretroviral Therapy Ann Intern Med, September 19, 2000; 133(6): 471 - 473. [Full Text] [PDF]
|
|
|
|
|
|
J. Blankson and R. F. Siliciano Interleukin 2 Treatment for HIV Infection JAMA, July 12, 2000; 284(2): 236 - 238. [Full Text] [PDF]
|
|
|
|
 |
|
 Antiretroviral Failure: A Biopsychosocial Approach AIDS Clinical Care, March 1, 2000; 2000(301): 1 - 1. [Full Text]
|
|
|
|
|
|
K. Henry The Case for More Cautious, Patient-Focused Antiretroviral Therapy Ann Intern Med, February 15, 2000; 132(4): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sulkowski, D. L. Thomas, R. E. Chaisson, and R. D. Moore Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection JAMA, January 5, 2000; 283(1): 74 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Niubò, W. Li, K. Henry, and A. Erice Recovery and Analysis of Human Immunodeficiency Virus Type 1 (HIV) RNA Sequences from Plasma Samples with Low HIV RNA Levels J. Clin. Microbiol., January 1, 2000; 38(1): 309 - 312. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Mellors Adefovir for the Treatment of HIV Infection: If Not Now, When? JAMA, December 22, 1999; 282(24): 2355 - 2356. [Full Text] [PDF]
|
|
|
|
|
|
N. Clumeck Choosing the Best Initial Therapy for HIV-1 Infection N. Engl. J. Med., December 16, 1999; 341(25): 1925 - 1926. [Full Text]
|
|
|
|
|
|
Therapy of Early HIV Infection: Time for the Pendulum to Swing Back? AIDS Clinical Care, October 1, 1999; 1999(1001): 1 - 1. [Full Text]
|
|
|
|
|
|
More Studies of Virologic Failure AIDS Clinical Care, September 1, 1999; 1999(901): 3 - 3. [Full Text]
|
|
|
|
 |
|
 Effectiveness of HIV HAART in Clinical Practice Journal Watch (General), August 6, 1999; 1999(806): 1 - 1. [Full Text]
|
|
|
|
|
|
|
Article
